Home > In process > TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism. > print

001     285462
005     20260306130553.0
024 7 _ |a 10.1038/s41467-026-68706-8
|2 doi
024 7 _ |a pmid:41580393
|2 pmid
024 7 _ |a pmc:PMC12936096
|2 pmc
037 _ _ |a DZNE-2026-00240
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Feiten, Astrid Feentje
|0 P:(DE-2719)9002289
|b 0
|e First author
|u dzne
245 _ _ |a TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism.
260 _ _ |a [London]
|c 2026
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772798197_9097
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial activity and loss-of-function coding variants are major risk factors for late onset Alzheimer's disease (LOAD). To better understand the molecular and functional changes associated with TREM2 signalling in microglia, we generated a TREM2 reporter mouse. In APP transgenic animals, bulk RNA-sequencing of isolated microglia sorted based on reporter expression highlighted TREM2 level-related changes in major immunometabolic pathways, and enrichment of genes in oxidative phosphorylation and cholesterol metabolism in microglia with increased TREM2 expression. Metabolic and lipidomic profiling of sorted microglia showed that, independent of Aβ pathology, TREM2 expression correlated with signatures consistent with increased cellular redox, energetics, and cholesterol homoeostasis. In accordance, metabolic activity correlated with phagocytic capacity. Finally, we performed chronic treatment with a TREM2 agonist antibody and identified a window of TREM2 expression where microglia are most responsive, thereby informing clinical applications of TREM2 agonists.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 1
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
693 _ _ |0 EXP:(DE-2719)PRECISE-20190321
|5 EXP:(DE-2719)PRECISE-20190321
|e Platform for Single Cell Genomics and Epigenomics at DZNE University of Bonn
|x 0
700 1 _ |a Dahm, Kilian
|0 P:(DE-2719)9001875
|b 1
|e First author
700 1 _ |a Schlepckow, Kai
|0 P:(DE-2719)2812546
|b 2
|e First author
700 1 _ |a van Lengerich, Bettina
|b 3
700 1 _ |a Suh, Jung H
|0 0000-0001-8119-326X
|b 4
700 1 _ |a Reifschneider, Anika
|b 5
700 1 _ |a Wefers, Benedikt
|0 P:(DE-2719)2810988
|b 6
700 1 _ |a Bartos, Laura M
|b 7
700 1 _ |a Wind, Karin
|0 P:(DE-2719)9001653
|b 8
|u dzne
700 1 _ |a de Weerd, Lis
|0 P:(DE-2719)9001304
|b 9
700 1 _ |a Ulas, Thomas
|0 P:(DE-2719)9000845
|b 10
|u dzne
700 1 _ |a De-Domenico, Elena
|0 P:(DE-2719)9000846
|b 11
700 1 _ |a Grundschöttel, Pia
|0 P:(DE-2719)9002695
|b 12
|u dzne
700 1 _ |a Paulusch, Stefan
|0 P:(DE-2719)9002116
|b 13
|u dzne
700 1 _ |a Tast, Benjamin
|b 14
700 1 _ |a Honda, Tamisa
|0 0000-0001-5654-1162
|b 15
700 1 _ |a Müller, Stephan A
|0 P:(DE-2719)2810938
|b 16
700 1 _ |a Becker, Matthias
|0 P:(DE-2719)2812750
|b 17
700 1 _ |a Khalin, Igor
|0 0000-0003-1041-5747
|b 18
700 1 _ |a Ricci, Alessio
|0 0000-0002-3051-8113
|b 19
700 1 _ |a Liesz, Arthur
|0 0000-0002-9069-2594
|b 20
700 1 _ |a Brunner, Bettina
|0 P:(DE-2719)2810716
|b 21
|u dzne
700 1 _ |a Krenner, Claudia
|0 P:(DE-2719)9002298
|b 22
|u dzne
700 1 _ |a Buschmann, Katrin
|0 P:(DE-2719)9002284
|b 23
|u dzne
700 1 _ |a Nuscher, Brigitte
|0 P:(DE-2719)9000236
|b 24
700 1 _ |a Spieth, Lena
|0 P:(DE-2719)9002306
|b 25
|u dzne
700 1 _ |a Junker, Niklas
|0 P:(DE-2719)9003939
|b 26
|u dzne
700 1 _ |a Berghoff, Stefan A
|0 P:(DE-2719)9001700
|b 27
|u dzne
700 1 _ |a Davis, Sonnet S
|b 28
700 1 _ |a Neher, Jonas J
|0 P:(DE-2719)2811021
|b 29
700 1 _ |a Wurst, Wolfgang
|0 P:(DE-2719)2000028
|b 30
700 1 _ |a Plesnila, Nikolaus
|0 P:(DE-2719)9000853
|b 31
700 1 _ |a Lewcock, Joseph W
|0 0000-0003-3012-7881
|b 32
700 1 _ |a Simons, Mikael
|0 P:(DE-2719)2811642
|b 33
700 1 _ |a Lichtenthaler, Stefan F
|0 P:(DE-2719)2181459
|b 34
700 1 _ |a Di Paolo, Gilbert
|0 0000-0003-1032-1265
|b 35
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 36
700 1 _ |a Capell, Anja
|0 P:(DE-2719)9000368
|b 37
700 1 _ |a Monroe, Kathryn M
|0 0000-0002-6901-1176
|b 38
700 1 _ |a Schultze, Joachim L
|0 P:(DE-2719)2811660
|b 39
700 1 _ |a Haass, Christian
|0 P:(DE-2719)2202037
|b 40
|e Last author
773 _ _ |a 10.1038/s41467-026-68706-8
|g Vol. 17, no. 1, p. 2002
|0 PERI:(DE-600)2553671-0
|n 1
|p 2002
|t Nature Communications
|v 17
|y 2026
|x 2041-1723
856 4 _ |u https://pub.dzne.de/record/285462/files/DZNE-2026-00240.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285462/files/DZNE-2026-00240.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002289
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001875
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2812546
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2810988
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)9001653
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9001304
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9000845
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9000846
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9002695
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)9002116
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2810938
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2812750
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2810716
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)9002298
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)9002284
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)9002306
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)9003939
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)9001700
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2811021
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2000028
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)2811642
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 34
|6 P:(DE-2719)2181459
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 36
|6 P:(DE-2719)9001539
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 37
|6 P:(DE-2719)9000368
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 39
|6 P:(DE-2719)2811660
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 40
|6 P:(DE-2719)2202037
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 2
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT COMMUN : 2022
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-08-21T14:06:14Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-08-21T14:06:14Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2025-08-21T14:06:14Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2025-11-10
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NAT COMMUN : 2022
|d 2025-11-10
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-10
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-10
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1013038
|k AG Schultze
|l Clinical Single Cell Omics (CSCO) / Systems Medicine
|x 1
920 1 _ |0 I:(DE-2719)1110006
|k AG Lichtenthaler
|l Neuroproteomics
|x 2
920 1 _ |0 I:(DE-2719)5000079
|k AG Becker
|l Modular High Performance Computing and Artificial Intelligence
|x 3
920 1 _ |0 I:(DE-2719)1110011
|k AG Neher (München)
|l Neuroimmunology and Neurodegenerative Disease
|x 4
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 5
920 1 _ |0 I:(DE-2719)1140001
|k AG Wurst
|l Genome Engineering
|x 6
920 1 _ |0 I:(DE-2719)1013031
|k PRECISE
|l Platform for Single Cell Genomics and Epigenomics
|x 7
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1013038
980 _ _ |a I:(DE-2719)1110006
980 _ _ |a I:(DE-2719)5000079
980 _ _ |a I:(DE-2719)1110011
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a I:(DE-2719)1140001
980 _ _ |a I:(DE-2719)1013031
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21